What Antares Therapeutics does

Antares Therapeutics is a privately held biotechnology company founded in 2025 and headquartered in Boston, Massachusetts (with a second office in South San Francisco), focused on developing first-in-class precision medicines for cancer and other serious diseases. The company operates a proprietary Covalent Drug Discovery Engine that integrates three capabilities: medicinal chemistry (proprietary compound libraries, next-generation mass spectrometry, pocket-finding approaches), target biology (human genetics, functional genomics, and patient population definition against first-in-class or best-through-first allosteric targets), and predictive sciences (physics-based approaches, machine learning, molecular dynamics, and proprietary algorithms). The platform inherits the validated pipeline and team built at predecessor Scorpion Therapeutics, which generated six development candidates including three in clinical testing prior to Eli Lilly's March 2025 acquisition of Scorpion's PI3Kα program.

The company's revenue model is partnership-driven and asset-light. Antares leads discovery internally until partners exercise options or license programs, with monetization through upfront payments, development and regulatory milestones, commercial milestones, and tiered royalties on global net sales. Existing economics include a $105M upfront plus up to $1.8B in milestones plus tiered royalties from the June 2026 Novartis collaboration covering undruggable cancer targets, plus retained milestone and royalty rights on the EGFR inhibitor programs out-licensed to Pierre Fabre (PFL-721, PFL-241) and on the PARP1 inhibitor (MOMA-989) licensed to Moma Therapeutics. The company also continues an AstraZeneca collaboration on transcription factors. Customers are therefore large pharmaceutical partners rather than end payers, and Antares retains the precision medicine portfolio it advances independently. The lead precision oncology program is expected to enter clinical testing in 2026, with multiple additional preclinical programs in development.

Name

Antares Therapeutics

Legal name

Antares Therapeutics, Inc.

Website

https://antaresrx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

101–250 employees

Short description

Antares Therapeutics is a Boston-based biotech developing first-in-class precision small molecule medicines for cancer by integrating covalent chemistry, target biology, and ML-driven predictive sciences, monetizing through pharma partnerships, milestones, and royalties.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Precision oncology therapeutics
• Small molecule discovery
• Drug development platform
• Covalent drug design
• Biotech research services

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Partnership Milestone Payments: Antares receives upfront payments and is eligible for development, regulatory, and commercial milestone payments from pharmaceutical partners. For the Novartis partnership, Antares received $105 million upfront with up to $1.8 billion in additional milestone payments.
2. Royalties on Net Sales: Tiered royalties on global net sales of any approved drugs developed through partnerships. The Novartis deal includes tiered royalties on global net sales.
3. Program Sales and Milestones: Antares receives regulatory and commercial milestones and tiered royalties from programs sold to partners, such as the two clinical-stage mutant EGFR inhibitors sold to Pierre Fabre Laboratories.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Antares Therapeutics is a clinical-stage biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, with a focus on targets that have been validated as disease drivers but historically considered undruggable. The company operates a proprietary Covalent Drug Discovery Engine that integrates covalent drug design, chemical proteomics, structure-driven computation, and machine learning to identify small molecule candidates, advancing programs both independently and through strategic partnerships with major pharmaceutical companies.

Product overview

Antares Therapeutics is a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases. The company operates a unified discovery platform—the Covalent Drug Discovery Engine—that integrates medicinal chemistry, target biology, and predictive sciences to identify and develop small molecule therapies targeting historically undruggable pathways. The core offering consists of the discovery platform itself combined with proprietary preclinical pipeline programs. The lead precision oncology program is expected to enter clinical testing in 2026, with multiple additional programs in preclinical development. The company also advances programs through strategic collaborations including partnerships with AstraZeneca (transcription factor targeting) and Novartis (undruggable cancer targets).

Differentiator

Problem solved

Functional benefit

Products and services

• Covalent Drug Discovery Engine Proprietary integrated discovery platform combining proprietary compound libraries, next-generation mass spectrometry experimental and computational capabilities, target biology tools (human genetics, experimental model systems, functional genomics), and predictive sciences (machine learning, molecular dynamics, physics-based approaches, proprietary algorithms) to identify small molecule drug candidates against historically undruggable oncology targets.
• Lead Precision Oncology Program Antares' most advanced preclinical precision oncology candidate, targeting validated but previously undruggable oncology pathways with a first-in-class mechanism or a best-through-first allosteric approach to clinically validated targets. Designed for transformational improvements in selectivity, tolerability, and target coverage.
• Preclinical Pipeline Programs Collection of multiple preclinical small molecule programs in cancer and other serious diseases, leveraging the Covalent Drug Discovery Engine to address first-in-class preclinically validated targets and best-through-first allosteric approaches to clinically validated targets.

Quantifiable outcome

• Six development candidates generated from Scorpion platform, with three in clinical testing
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Novartis AGflagshipStrategic or Co-development Partner · 24 June 2026Strategic collaboration to discover, develop, and commercialize small molecule therapies targeting historically undruggable oncology targets. Antares receives $105 million upfront and up to $1.8 billion in milestone payments plus tiered royalties on global net sales. Antares leads all research using its proprietary discovery engine until Novartis exercises options.
• AstraZenecacoreStrategic or Co-development PartnerOngoing collaboration focused on transcription factors, a class of proteins that control gene expression and regulate important cellular processes including cell proliferation, differentiation and survival. Many transcription factors have long been validated as drivers of disease but have historically been considered undruggable. The collaboration aims to make every protein druggable.
• Pierre Fabre LaboratoriescoreStrategic or Co-development PartnerPierre Fabre acquired global rights to two clinical-stage, highly selective next-generation mutant EGFR inhibitors (PFL-721 and PFL-241) for non-small cell lung cancer, initially developed at Scorpion. Pierre Fabre leads continued clinical development and global commercialization. Antares eligible for regulatory and commercial milestones and tiered royalties.
• Moma TherapeuticscoreStrategic or Co-development PartnerMoma Therapeutics is continuing the development of Antares' next-generation, brain-penetrant, selective PARP1 inhibitor (MOMA-989) as monotherapy and in combination with their innovative pipeline targeting molecular machines.

Scale indicators8 records

Recent moves8 records

Direct peers

• Scorpion Therapeutics: Antares' predecessor company; shares the same founding scientific team, integrated discovery platform, and pipeline programs. Scorpion was acquired by Eli Lilly in 2025 for its PI3Kα program, providing the foundational assets that Antares was spun out to advance.
• Revolution Medicines: Clinical-stage oncology company developing targeted therapies for RAS-addicted cancers using proprietary tri-complex technology. Comparable as a precision oncology small molecule platform with multiple partnered and wholly-owned programs targeting historically challenging cancer targets.
• Relay Therapeutics: Precision oncology company using the Dynamo platform integrating computational chemistry, structural biology, and AI to drug difficult targets including PI3Kα mutants. Closely comparable in target selection (mutant-selective oncology), platform approach, and clinical-stage status.
• Black Diamond Therapeutics: Precision oncology company developing small molecule allosteric inhibitors targeting undruggable oncogenic proteins, including transcription factors and other historically challenging cancer targets. Highly comparable discovery strategy and target class.
• Foghorn Therapeutics: Clinical-stage company developing medicines targeting the chromatin regulatory system, including transcription factors and other chromatin-related proteins long considered undruggable. Directly comparable target class focus and platform strategy.
• Moma Therapeutics: Emerging precision oncology company developing drugs targeting molecular machines including PARP1 inhibitors and other DNA damage response targets. Active Antares partner advancing MOMA-989 (brain-penetrant PARP1 inhibitor), making it a directly comparable and partnered peer.
• ORIC Pharmaceuticals: Clinical-stage oncology company developing small molecule inhibitors addressing resistance mechanisms in cancer treatment. Shares similar organizational structure, target-class focus (difficult oncology targets), and Boston-area biotech ecosystem.

Broad incumbents

• Blueprint Medicines: Established precision medicine company targeting kinases and other genomically defined drivers of disease, with multiple approved products (Ayvakit, Gavreto). Shares the same founding scientific team lineage as Antares and is a direct talent/technology competitor.
• Mirati Therapeutics: Targeted oncology company developing small molecule inhibitors of KRAS and other oncogenic drivers. Acquired by Bristol Myers Squibb for $4.8B in 2024. Comparable precision oncology focus with commercial-stage products demonstrating the M&A exit pathway.
• Schrödinger: Computational chemistry and physics-based drug discovery platform company with both internal pipeline and external partnerships. Comparable in the AI/ML-driven drug discovery approach, though broader in therapeutic area scope and with platform-services business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/antares_rx
• LinkedInlinkedin.com/company/antares-therapeutics
• Instagraminstagram.com/antares_rx

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antares Therapeutics